Examkin

Soru

Zorluk: ZorHemodynamic and Coagulation Processes

A 7676-year-old man is brought to the emergency department by his daughter after he vomited approximately 500500 mL of bright red blood. He has a history of nonvalvular atrial fibrillation, hypertension, and osteoarthritis. His medications include dabigatran, lisinopril, and ibuprofen. For the past 33 days, he has had a diarrheal illness with poor oral intake. On presentation, he appears pale and diaphoretic. Blood pressure is 86/5486/54 mm Hg, and pulse is 118118/min.

Laboratory results are as follows:
- Hemoglobin: 7.27.2 g/dL
- Platelet count: 210,000210,000/mm 3^3
- Creatinine: 3.43.4 mg/dL (baseline 1.21.2 mg/dL)
- Prothrombin time (PT): 1616 seconds
- Activated partial thromboplastin time (aPTT): 7272 seconds

The patient is given intravenous crystalloids and packed red blood cells. A specific pharmacologic antidote is administered to rapidly neutralize the circulating anticoagulant. Which of the following best describes the mechanism of action of this antidote?

  1. Binding and neutralization of the anticoagulant by a humanized monoclonal antibody fragmentCevap
  2. B
    Sequestration of the anticoagulant by a catalytically inactive recombinant factor Xa analog
  3. C
    Formation of a stable, inactive salt complex via a highly positively charged peptide
  4. D
    Promotion of gamma-carboxylation of glutamic acid residues on specific coagulation factors
  5. E
    Competitive inhibition of plasminogen activation to prevent fibrin degradation

Cevap

Binding and neutralization of the anticoagulant by a humanized monoclonal antibody fragment
This patient presents with a life-threatening gastrointestinal hemorrhage secondary to dabigatran toxicity. His pre-renal acute kidney injury—triggered by volume depletion from diarrhea and exacerbated by concurrent use of lisinopril (efferent arteriole vasodilation) and ibuprofen (afferent arteriole vasoconstriction)—has led to decreased renal clearance and subsequent accumulation of dabigatran. Dabigatran is a direct thrombin (factor IIa) inhibitor. The specific and targeted reversal agent for dabigatran is idarucizumab. Idarucizumab is a humanized monoclonal antibody fragment that binds to both free and thrombin-bound dabigatran with extremely high affinity, rapidly neutralizing its anticoagulant effect.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation and laboratory results.
The patient has life-threatening gastrointestinal bleeding and an elevated creatinine (3.43.4 mg/dL from 1.21.2 mg/dL), indicating acute kidney injury (AKI). Coagulation studies show a significantly prolonged aPTT.
Identifying the severity of bleeding and the presence of AKI helps determine the cause of the coagulopathy.
2
Correlate the patient's medications with the current clinical picture.
The patient is taking dabigatran, lisinopril, and ibuprofen. The combination of volume depletion (diarrhea), an ACE inhibitor, and an NSAID has caused pre-renal AKI. Dabigatran, a direct thrombin inhibitor, is 80%80\% renally cleared and has accumulated, causing toxicity and bleeding.
Understanding the pharmacokinetics of dabigatran is crucial; renal impairment is the primary risk factor for dabigatran toxicity.
3
Identify the appropriate management and mechanism of action for the targeted reversal agent.
The specific antidote for dabigatran is idarucizumab, which is a humanized monoclonal antibody fragment designed to bind and neutralize dabigatran.
Reversing the specific drug responsible for the hemorrhage is the definitive management step in life-threatening bleeding.

Anahtar Kavram

Dabigatran is a direct thrombin inhibitor that is primarily renally excreted; its toxicity in the setting of acute kidney injury is reversed with idarucizumab, a specific humanized monoclonal antibody fragment.
Bu soruyu puanla

Konular

Hemodynamic and Coagulation Processes

Bu konudan daha fazla soru